Following recent constructive FDA feedback, Seres anticipates finalizing SER-155 Phase 2 study protocol for the prevention of bloodstream infections in…
Open-label study evaluated a two-dose induction regimen of BPL-003 (8 mg followed by 12 mg two weeks later) in patients…
KING OF PRUSSIA, Pa., Sept. 23, 2025 (GLOBE NEWSWIRE) -- SEED Therapeutics, Inc. (“SEED”), a clinical-stage biotechnology company pioneering rational…
Slava Akmaev, Ph.D. BPGbio Welcomes Back NAi Interrogative Biology® Platform Co-Inventor Slava Akmaev, Ph.D., as Chief Operating Officer and Chief…
Semnur’s shares of common stock and warrants are expected to trade on the OTC Markets on September 23, 2025 under…
Registration Link Below for September 30, 2025 12 PM EST Presentation and Live Q&AKing of Prussia, Pennsylvania--(Newsfile Corp. - September…
Global AI in Oncology For Analytical Solutions Market to Transform Cancer Care Accelerating Early Detection, Precision Treatment, and Patient Outcomes.…
Hemogenyx Pharmaceuticals Signs Letter of Intent with Cellin Technologies to Advance Commercialization of HG-CT-1 CAR-T Therapy in EstoniaFirst Potential Near-Term…
VANCOUVER, BC / ACCESS Newswire / September 22, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(Frankfurt:W1H, WKN: A3EKSZ)(OTCQB:ONNVF) ("Onco" or the "Company")…
BARCELONA, Spain and DÜSSELDORF, Germany, Sept. 22, 2025 /PRNewswire/ -- Neuraxpharm Group (Neuraxpharm), a leading European pharmaceutical company focused on…